JP2015512949A5 - - Google Patents

Download PDF

Info

Publication number
JP2015512949A5
JP2015512949A5 JP2015505963A JP2015505963A JP2015512949A5 JP 2015512949 A5 JP2015512949 A5 JP 2015512949A5 JP 2015505963 A JP2015505963 A JP 2015505963A JP 2015505963 A JP2015505963 A JP 2015505963A JP 2015512949 A5 JP2015512949 A5 JP 2015512949A5
Authority
JP
Japan
Prior art keywords
cyclodextrin
composition
diabetes
cholesterol
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015505963A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512949A (ja
JP6491089B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/036484 external-priority patent/WO2013155485A2/en
Publication of JP2015512949A publication Critical patent/JP2015512949A/ja
Publication of JP2015512949A5 publication Critical patent/JP2015512949A5/ja
Application granted granted Critical
Publication of JP6491089B2 publication Critical patent/JP6491089B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015505963A 2012-04-13 2013-04-12 シクロデキストリンを使用するための方法 Active JP6491089B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261624087P 2012-04-13 2012-04-13
US61/624,087 2012-04-13
PCT/US2013/036484 WO2013155485A2 (en) 2012-04-13 2013-04-12 Method of using cyclodextrin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018150978A Division JP2018203747A (ja) 2012-04-13 2018-08-10 シクロデキストリンを使用するための方法

Publications (3)

Publication Number Publication Date
JP2015512949A JP2015512949A (ja) 2015-04-30
JP2015512949A5 true JP2015512949A5 (cg-RX-API-DMAC7.html) 2016-06-09
JP6491089B2 JP6491089B2 (ja) 2019-03-27

Family

ID=49328287

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015505963A Active JP6491089B2 (ja) 2012-04-13 2013-04-12 シクロデキストリンを使用するための方法
JP2018150978A Pending JP2018203747A (ja) 2012-04-13 2018-08-10 シクロデキストリンを使用するための方法
JP2021103893A Pending JP2021155436A (ja) 2012-04-13 2021-06-23 シクロデキストリンを使用するための方法
JP2023146755A Pending JP2023178518A (ja) 2012-04-13 2023-09-11 シクロデキストリンを使用するための方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018150978A Pending JP2018203747A (ja) 2012-04-13 2018-08-10 シクロデキストリンを使用するための方法
JP2021103893A Pending JP2021155436A (ja) 2012-04-13 2021-06-23 シクロデキストリンを使用するための方法
JP2023146755A Pending JP2023178518A (ja) 2012-04-13 2023-09-11 シクロデキストリンを使用するための方法

Country Status (8)

Country Link
US (4) US10195227B2 (cg-RX-API-DMAC7.html)
EP (2) EP2836221B1 (cg-RX-API-DMAC7.html)
JP (4) JP6491089B2 (cg-RX-API-DMAC7.html)
CN (2) CN111419870A (cg-RX-API-DMAC7.html)
CA (1) CA2870316C (cg-RX-API-DMAC7.html)
ES (1) ES2959119T3 (cg-RX-API-DMAC7.html)
MX (2) MX392972B (cg-RX-API-DMAC7.html)
WO (1) WO2013155485A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419870A (zh) * 2012-04-13 2020-07-17 L&F研究有限公司 使用环糊精的方法
CA3162739A1 (en) 2013-03-12 2014-10-02 Primal Therapies, Inc. Dental composition comprising chelator and base
JP6418911B2 (ja) * 2014-11-18 2018-11-07 学校法人中部大学 Ｇｌｐ−１分泌促進剤
AU2016276774A1 (en) 2015-06-10 2018-01-18 Vtesse, Inc. Hydroxypropyl beta-cyclodextrin compositions and methods
CN105395549A (zh) * 2015-11-03 2016-03-16 天津医科大学总医院 烟酸的新用途
CA3037286A1 (en) * 2016-09-19 2018-03-22 Aten Porus Lifesciences Cyclodextrin based polymers, methods, compositions and applications thereof
WO2018075622A1 (en) * 2016-10-19 2018-04-26 University Of Miami Materials and methods for modulating insulin signaling and preserving podocyte function
CN107982546A (zh) * 2017-12-05 2018-05-04 中国药科大学 基于主客体相互作用的酸敏感超分子纳米粒及其应用
ES2992137T3 (es) 2018-10-29 2024-12-09 Cyclo Therapeutics Inc Métodos para tratar la enfermedad de Alzheimer con HP-[ß]-ciclodextrina
CA3125554A1 (en) 2019-01-03 2020-07-09 Underdog Pharmaceuticals, Inc. Cyclodextrin dimers, compositions thereof, and uses thereof
PH12021552553A1 (en) * 2019-04-16 2022-06-20 Celagenex Res India Pvt Ltd Synergistic lipid controlling compositions
CN115052983A (zh) * 2019-11-11 2022-09-13 A·越智 重编程体细胞的方法和试剂盒
US12226431B2 (en) 2021-09-11 2025-02-18 Porosome Therapeutics, Inc. Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses
WO2022047249A1 (en) * 2020-08-27 2022-03-03 Beren Therapeutics P.B.C. Methods for the treatment of cardiovascular disease with cyclodextrins
US20230302042A1 (en) * 2020-08-27 2023-09-28 Beren Therapeutics P.B.C. Methods for the prevention of cholesterol crystal embolization with cyclodextrins
US20230330133A1 (en) * 2020-08-27 2023-10-19 Beren Therapeutics P.B.C. Methods for the treatment of cholesterol crystal embolization with cyclodextrins
CN112089843B (zh) * 2020-10-13 2022-11-04 合肥工业大学 一种抗心力衰竭的联用组合药物及其在制备抗心力衰竭药物中的应用
JP2024509376A (ja) * 2021-02-18 2024-03-01 ベレン セラピューティクス ピー．ビー．シー． 家族性ヘテロ接合型及びホモ接合型高コレステロール血症のシクロデキストリンによる治療方法
CN113295793B (zh) * 2021-05-20 2022-11-04 复旦大学附属中山医院 预测早期糖尿病以及糖尿病发生的生物标志物、其检测方法与应用
US20240238327A1 (en) * 2021-09-01 2024-07-18 Renatus Inc. Pharmaceutical composition comprising gamma-cyclodextrin polymer and uses thereof
WO2023156966A1 (en) 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0672100B2 (ja) 1989-11-15 1994-09-14 株式会社上野製薬応用研究所 利尿剤
US5840713A (en) * 1995-04-03 1998-11-24 Weisz; Paul B. Therapy for tissue membrane insufficiency
AU6366999A (en) * 1998-10-30 2000-05-22 Takeda Chemical Industries Ltd. Betacellulin protein-containing preparations
US6756504B2 (en) * 2000-04-19 2004-06-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingolipids
US20040121983A1 (en) 2002-08-12 2004-06-24 Council Of Scientific And Industrial Research Method for treating leishmaniasis using methyl-beta-cyclodextrin
PL213863B1 (pl) 2002-08-19 2013-05-31 Art Jen Complexus Konsumpcyjny maczny produkt zywnosciowy, konsumpcyjny niemaczny produkt zywnosciowy, sposób polepszania organoleptycznych wlasciwosci zawierajacego tluszcz konsumpcyjnego produktu zywnosciowego i sposób zmniejszania dostepnosci biologicznej tluszczu w konsumpcyjnym zawierajacym tluszcz produkcie zywnosciowym
JP2004323443A (ja) * 2003-04-25 2004-11-18 Tokai Univ 抗血栓薬
EP1635813A4 (en) * 2003-06-06 2009-07-01 Merck & Co Inc COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA
US9200245B2 (en) 2003-06-26 2015-12-01 Seng Enterprises Ltd. Multiwell plate
US7393826B2 (en) * 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US7276351B2 (en) 2003-09-10 2007-10-02 Seahorse Bioscience Method and device for measuring multiple physiological properties of cells
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
CN1282425C (zh) * 2004-06-22 2006-11-01 王美岭 苹果醋营养品及其生产方法
US20060128653A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
JP2006191830A (ja) * 2005-01-12 2006-07-27 Unitika Ltd 脂肪の蓄積を抑制する食品
WO2006081364A2 (en) * 2005-01-27 2006-08-03 Erimos Pharmaceuticals Llc Formulations for injection of catecholic butanes, including ndga compounds, into animals
WO2007056435A2 (en) 2005-11-08 2007-05-18 The General Hospital Corporation Dynamin mediated diseases and associated methods and products
US20090324624A1 (en) 2006-06-16 2009-12-31 Florida Atlantic University Chitin micro-particles as an adjuvant
EP1894924A1 (en) * 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
WO2008067027A2 (en) * 2006-10-20 2008-06-05 Icos Corporation Compositions of chkl inhibitors and cyclodextrin
EP1920785A1 (en) * 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
WO2010042202A1 (en) 2008-10-07 2010-04-15 Fibrogen, Inc. Methods for treatment of podocyte injury
JP2012505251A (ja) * 2008-10-10 2012-03-01 リメリック バイオファーマ， インコーポレイテッド 代謝性疾患の処置のためのピロン
US8202702B2 (en) 2008-10-14 2012-06-19 Seahorse Bioscience Method and device for measuring extracellular acidification and oxygen consumption rate with higher precision
US8263413B1 (en) 2008-10-17 2012-09-11 Andrew S Hansen Methods for analyzing lipids and membrane proteins in biological matter using stable isotopes and mass spectrometry
US20110236397A1 (en) 2008-11-06 2011-09-29 University Of Miami Limited proteolysis of cd2ap and progression of renal disease
US20110314423A1 (en) 2009-03-12 2011-12-22 Panasonic Corporation Image display device and image display method
JP5847721B2 (ja) * 2009-10-08 2016-01-27 ソン、ホ、バイオメッド、カンパニー、リミテッドＳｏｎｇ Ｈｏ Ｂｉｏｍｅｄ Ｃｏ．， Ｌｔｄ 高水溶性２−ヒドロキシプロピル−ベータシクロデキストリンを有効成分として含有する、肥満疾患の予防および治療用組成物
US20120251527A1 (en) 2009-11-06 2012-10-04 University Of Miami Podocyte specific assays and uses thereof
US8372877B2 (en) * 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
EP2595623B1 (en) * 2010-07-19 2018-02-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Use of delta tocopherol for the treatment of lysosomal storage disorders
US10052345B2 (en) 2010-10-19 2018-08-21 University Of Miami Assays, methods and kits for predicting renal disease and personalized treatment strategies
CN111419870A (zh) * 2012-04-13 2020-07-17 L&F研究有限公司 使用环糊精的方法

Similar Documents

Publication Publication Date Title
JP2015512949A5 (cg-RX-API-DMAC7.html)
Jeong Nonalcoholic fatty liver disease: a drug revolution is coming
Ma et al. Methyl protodioscin increases ABCA1 expression and cholesterol efflux while inhibiting gene expressions for synthesis of cholesterol and triglycerides by suppressing SREBP transcription and microRNA 33a/b levels
US20240358718A1 (en) Concomitant administration of glucocorticoid receptor modulators and cyp3a inhibitors
JP5302900B2 (ja) 脂肪性肝疾患の治療用医薬組成物
CN103717219A (zh) 左心室舒张功能改善剂
JP2011512347A5 (cg-RX-API-DMAC7.html)
Parfianowicz et al. Finerenone: a new era for mineralocorticoid receptor antagonism and cardiorenal protection
AU2014259352B2 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
CA3044364A1 (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease
Li et al. GLP-1R in diabetes mellitus: from basic discovery to therapeutics development
ES2525748T3 (es) Agente terapéutico o profiláctico para la diabetes
CA3137138A1 (en) Methods of treating hypertension with activators of tie-2
US20220265776A1 (en) Combination
WO2014036603A1 (en) Uses of (-)-perhexiline
WO2023026247A1 (en) Combination of a nurr1 agonist with at least one of an aldosterone antagonist, an insulin modulator and a sulfonylurea
JP2016183111A (ja) Ｎｒｆ２活性化剤
Tan et al. Therapeutic Potential of Metformin in Diabetes Mellitus-Related Cardiovascular Complications
EP4527385A1 (en) Il-6 and/or il-1? inhibitor
JP4433496B2 (ja) Ａｔｐクエン酸リアーゼの発現抑制用医薬組成物及びその使用
Pleasants Medication safety in chronic lung disease with cardiac comorbidity
WO2011121182A1 (en) Pharmaceutical composition comprising gemfibrozil and cyp2c8 and/or oatp substrate drug such as repaglinide
JPH11189537A (ja) プロスタグランジン類の医薬用途
HK40063597A (en) Methods of treating hypertension with activators of tie-2
JP2010520854A (ja) 高コレステロール血症の治療又は予防において使用するためのニトロキシド